Basel 5 May 2008
Roche
Science Events: ASCO 2008
Analyst briefings on data presented at ASCO
New
in 2008: Roche IR Events on Sunday and Monday
We are pleased to invite
you to our Analyst briefings to discuss data presented by Roche at the American Society of Clinical
Oncology meeting (ASCO) in Chicago.
New in 2008: Roche is offering two
Analyst briefings, one on Sunday evening and one on Monday evening, to cover the rich newsflow in a
timely manner.
Several presentations will be given by leading Investigators
/ Key Opinion Leaders as well as Roche product experts.
Venue:
Hotel Hyatt Regency McCormick Place (next to the Conference Center)
Please
see below for details on each of our ASCO Analyst briefings.
Date/Time:
Sunday, 1st June, 2008
 | Roche ASCO IR event
(part 1)
Meeting room: please check the event board on site prior to the event
06.30
pm to 07.30 pm CDT (Chicago)
01.30 am to 02.30 am CEST (Zurich) on 2nd June, 2008
00.30
am to 01.30 am BST (London) on 2nd June, 2008 |
Highlights:
| Dr. David Miles, Consultant Medical
Oncologist,
Mount Vernon Hospital, |
| Middlesex,
UK, Principal Investigator of AVADO study
AVADO study results: Avastin in combination
with docetaxel in metastatic breast cancer
Dr. Stefan Frings, Life
Cycle Leader Avastin, Roche
Update on Avastin development program in breast cancer and
highlights from the over 180 abstracts on Avastin accepted by ASCO
Other
key members of Roche product teams will also be available for Q&A |
Venue:
Hotel Hyatt Regency McCormick Place, Chicago
Analysts are invited
to dial in to the conference call using the following dial-in numbers:
| +41
(0) 91 610 56 00 (Europe)
+1 (1) 866 291 4166 (USA)
+44 (0) 207
107 0611 (UK) |
Please dial in to the conference
call 10 – 15 minutes before the call is scheduled to start.
A replay
of the conference call will be available one hour after the conference call, for 48 hours.
Access
is by dialing:
| +41 (0) 91 612 43 30 (Europe)
+1
(1) 866 416 2558 (USA)
+44 (0) 207 108 6233 (UK) |
| Listeners
will be asked to enter the ID 18582 followed by the # sign |
The
presentation slides will be available from the IR website at http://ir.roche.com
following the closure of the ASCO meeting.
Date/Time:
Monday,
2nd June, 2008
| Roche ASCO IR event (part
2)
Meeting room: please check the event board on site prior to the event
06.30
pm to 08.00 pm CDT (Chicago)
01.30 am to 03.00 am CEST (Zurich) on 3rd June, 2008
00.30
am to 02.00 am BST (London) on 3rd June, 2008 |
Highlights:
| Prof. Dr. Alberto Sobrero,
Head Medical Oncology Unit, Ospedale San Martino, Genova,
Italy
Avastin in colorectal cancer: clinical
trials and real
life experience
Dr. Niko André, International Medical Leader Avastin,
Roche
New data on Avastin in colorectal cancer including Kras subgroup analysis
Prof.
Dr. José Baselga, Chairman and Professor of Medicine, Medical Oncology Service,
Vall d’Hebron University Hospital, Barcelona, Spain.
Principal investigator of pertuzumab
breast cancer study
New results of GBG26 study: Herceptin efficacy data in Herceptin
pre-treated patients. Phase II study of pertuzumab in combination with Herceptin.
Other
key members of Roche product teams will also be available for Q&A |
Venue:
Hotel Hyatt Regency McCormick Place, Chicago
Analysts are invited
to dial in to the conference call using the following dial-in numbers:
| +41
(0) 91 610 56 00 (Europe)
+1 (1) 866 291 4166 (USA)
+44 (0) 207
107 0611 (UK) |
Please dial in to the conference
call 10 – 15 minutes before the call is scheduled to start.
Alternatively,
a live audio webcast can be accessed via http://ir.roche.com
(listen only, no access to speakers). A replay of the conference call will be available
one hour after the conference call, for 48 hours.
| Access is
by dialing:
+41 (0) 91 612 43 30 (Europe)
+1 (1) 866 416 2558 (USA)
+44
(0) 207 108 6233 (UK)
Listeners will be asked to enter the ID 18335
followed by the # sign
|
The presentation slides will
be available from the IR website at http://ir.roche.com following the closure of
the ASCO meeting.Registration Form |
 |
print this page